BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Befotertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Befotertinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07809815-2235@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Befotertinib: Phase 1 readout est. (NCT07809815)
DESCRIPTION:Befotertinib\, phase 1.\nStudy: Drug-Drug Interaction Study of 
 Befotertinib Capsules in Healthy Participants.\nEstimated primary completi
 on: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/befot
 ertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07809815
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561620-2235@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Befotertinib: Phase 4 readout est. (NCT06561620)
DESCRIPTION:Befotertinib\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Be
 fotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients\nEstimated prim
 ary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/befotertinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06561620
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863506-2235@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Befotertinib: Phase 2 readout est. (NCT06863506)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC\n
 Estimated primary completion: 30 June 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/befotertinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06863506
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06728865-2235@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Befotertinib: Phase 2 readout est. (NCT06728865)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ev
 aluation of the Efficacy and Safety of Befotertinib Combined With Bevacizu
 mab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer W
 ith Brain Metastases: A Single-Arm\, Open-Label\, Prospective Phase II Cli
 nical Study\nEstimated primary completion: 1 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/befotertinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06728865
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06041776-2235@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Befotertinib: Phase 3 readout est. (NCT06041776)
DESCRIPTION:Befotertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 juvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Posit
 ive EGFR Sensitive Mutations\nEstimated primary completion: 30 April 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/befotertinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06041776
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181499-2235@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Befotertinib: Phase 2 readout est. (NCT07181499)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Se
 quential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSC
 LC) Patients With Resistance to Third-Generation EGFR-TKI\nEstimated prima
 ry completion: November 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/befotertinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07181499
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06015568-2235@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20281104
DTEND;VALUE=DATE:20281105
SUMMARY:Befotertinib: Phase 1 readout est. (NCT06015568)
DESCRIPTION:Befotertinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of MCLA-129 Combined With Befotertinib in the Treatment of Advanced No
 n-small Cell Lung Cancer With EGFR Sensitive Mutation\nEstimated primary c
 ompletion: 4 November 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/befotertinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06015568
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900243-2235@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Befotertinib: Phase 4 readout est. (NCT07900243)
DESCRIPTION:Befotertinib\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: A 
 Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Ic
 otinib in Patients With Previously Untreated EGFR-sensitive Mutation-posit
 ive Non-small Cell Lung Cancer With ECOG Score ≥2\nEstimated primary com
 pletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/befotertinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07900243
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410611-2235@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Befotertinib: Phase 2 readout est. (NCT07410611)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: ct
 DNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined Wi
 th Radiotherapy\nEstimated primary completion: 28 February 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/befotertinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07410611
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709585-2235@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Befotertinib: Phase 2 readout est. (NCT07709585)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Be
 fotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Trea
 tment Escalation and Response Optimization in EGFR-mutated NSCLC Patients\
 nEstimated primary completion: 31 July 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/befotertinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07709585
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
